Novartis to present new data across oncology portfolio including Kisqali Phase III NATALEE trial in early breast cancer at ASCO

Novartis will present new data from its oncology portfolio at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting, including advancements in breast cancer, prostate cancer and lung cancer from more than 40 Novartis-sponsored and investigator-led trials. Primary results…

Read MoreNovartis to present new data across oncology portfolio including Kisqali Phase III NATALEE trial in early breast cancer at ASCO

Novartis Phase III APPOINT-PNH trial shows investigational oral monotherapy iptacopan improves hemoglobin to near-normal levels, leading to transfusion independence in all treatment-naïve PNH patients

 Novartis today announced detailed results from the Phase III APPOINT-PNH trial of investigational oral monotherapy iptacopan in complement-inhibitor-naïve (including anti-C5 therapies) adults with paroxysmal nocturnal hemoglobinuria (PNH)1. The trial met its primary endpoint and demonstrated clinically meaningful benefits across secondary…

Read MoreNovartis Phase III APPOINT-PNH trial shows investigational oral monotherapy iptacopan improves hemoglobin to near-normal levels, leading to transfusion independence in all treatment-naïve PNH patients

Novartis delivers strong sales growth, robust margin expansion and major innovation milestones. Raises FY guidance

Ad hoc announcement pursuant to Art. 53 LR Basel, April 25, 2023 – commenting on the quarter, Vas Narasimhan MD, CEO of Novartis, said: “Novartis delivered strong growth to start 2023, driven by our in-market growth brands, in particular Entresto, Kisqali and Kesimpta. The Pluvicto and Scemblix launches continue…

Read MoreNovartis delivers strong sales growth, robust margin expansion and major innovation milestones. Raises FY guidance

Novartis réalise une croissance forte de son chiffre d’affaires, une expansion robuste de sa marge, des étapes majeures de l’innovation et rehausse ses prévisions pour l’exercice 2023

Annonce événementielle au sens de l’art. 53 RC Bâle, le 25 avril 2023 – Commentant les résultats du T1, Dr Vas Narasimhan CEO de Novartis, a déclaré: «Novartis a commencé l’exercice 2023 en réalisant une forte croissance. Celle-ci a été assurée par nos…

Read MoreNovartis réalise une croissance forte de son chiffre d’affaires, une expansion robuste de sa marge, des étapes majeures de l’innovation et rehausse ses prévisions pour l’exercice 2023

Novartis erzielt kräftige Umsatzsteigerungen, eine robuste Margenerhöhung und wichtige Innovationsmeilensteine. Erhöhung der Jahresprognose

Ad-hoc-Mitteilung gemäss Art. 53 KR Basel, 25. April 2023 – Die Ergebnisse des ersten Quartals kommentierte Vas Narasimhan, CEO von Novartis: «Novartis ist mit einem kräftigen Wachstum in das Jahr 2023 gestartet, angetrieben durch unsere Wachstumsmarken im Markt, insbesondere Entresto, Kisqali und Kesimpta. Die Einführung von Pluvicto und Scemblix verläuft…

Read MoreNovartis erzielt kräftige Umsatzsteigerungen, eine robuste Margenerhöhung und wichtige Innovationsmeilensteine. Erhöhung der Jahresprognose

Novartis presents new five-year data on disability outcomes and safety of Kesimpta® (ofatumumab) in people living with relapsing multiple sclerosis

 Novartis today announced new long-term data from the ALITHIOS open-label extension study showing that up to five years, patients treated earlier and continuously with Kesimpta® (ofatumumab) had fewer disability worsening events and low brain volume change versus those who started on…

Read MoreNovartis presents new five-year data on disability outcomes and safety of Kesimpta® (ofatumumab) in people living with relapsing multiple sclerosis

Sandoz receives approval by European Commission for Hyrimoz® (adalimumab) high-concentration formulation

Sandoz, a global leader in off-patent (generic and biosimilar) medicines, today announced that the European Commission (EC) granted marketing authorization in the European Union (EU) for a citrate-free high concentration formulation (HCF; 100 mg/mL) of its biosimilar Hyrimoz® (adalimumab). The approval…

Read MoreSandoz receives approval by European Commission for Hyrimoz® (adalimumab) high-concentration formulation

Labcorp and Jefferson Health Announce Strategic Laboratory Relationship

Physicians and Patients Will Gain Access to Enhanced Laboratory Services and Advanced Diagnostic Testing BURLINGTON, N.C., May 3, 2023 /PRNewswire/ — Labcorp (NYSE: LH), a leading global life sciences company, today announced an agreement to enter into a strategic relationship with Jefferson Health (Jefferson), the largest…

Read MoreLabcorp and Jefferson Health Announce Strategic Laboratory Relationship

Labcorp expands access to colorectal cancer screening through partnership with the Conference of National Black Churches

 Labcorp (NYSE: LH), a leading global life sciences company, is partnering with the Conference of National Black Churches (CNBC) to address health equity gaps in colorectal cancer screening. To raise awareness and provide expanded access to colorectal cancer screening tests, the Conference of National…

Read MoreLabcorp expands access to colorectal cancer screening through partnership with the Conference of National Black Churches